Table 3 Objective response rate (according to the RECIST v1.1 criteria)

From: Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

Objective response

N (65)

%

95% CI

CR

3

4.6%

[0.9; 12.9]

PR

40

61.5%

[48.6; 73.3]

SD

14

21.5%

[12.3; 33.5]

PD

8

12.3%

[5.5; 22.8]

  1. CI confidence interval, CR complete response, PD progressive disease, PR partial response, SD stable disease
Back to article page